EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

Abdul Rafeh Naqash, Justin D McCallen, Emma Mi, Sanna Iivanainen iD, Mona A Marie, Daria Gramenitskaya, James Clark, Jussi Pekka Koivunen, Shravanti Macherla, Sweta Jonnalagadda, Shanker Polsani, Rahim Ali Jiwani und 13 weitere

Journal for ImmunoTherapy of Cancer · 2023-10 · 11 (10) · e007310

DOI: 10.1136/jitc-2023-007310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.10.2023. Verfasst von Abdul Rafeh Naqash und 24 weiteren Autor:innen. Beteiligte Einrichtung: Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA alessiocortellini@gmail.com abdulrafeh-naqa…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Wellcome Trust Strategic Fund, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic immune activation, hallmarked by C-reactive protein (CRP) and interleukin-6 (IL-6), can modulate antitumor immune responses. In this study, we evaluated the role of IL-6 and CRP in the stratification of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). We also interrogated the underlying immunosuppressive mechanisms driven by the IL-6/CRP axis.

Methods

In cohort A (n=308), we estimated the association of baseline CRP with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) in patients with NSCLC treated with ICIs alone or with chemo-immunotherapy (Chemo-ICI). Baseline tumor bulk RNA sequencing (RNA-seq) of lung adenocarcinomas (LUADs) treated with pembrolizumab (cohort B, n=59) was used to evaluate differential expression of purine metabolism, as well as correlate IL-6 expression with PFS. CODEFACS approach was applied to deconvolve cohort B to characterize the tumor microenvironment by reconstructing the cell-type-specific transcriptome from bulk expression. Using the LUAD cohort from The Cancer Genome Atlas (TCGA) we explored the correlation between IL-6 expression and adenosine gene signatures. In a third cohort (cohort C, n=18), plasma concentrations of CRP, adenosine 2a receptor (A2aR), and IL-6 were measured using ELISA.

Results

In cohort A, 67.2% of patients had a baseline CRP≥10 mg/L (CRP-H). Patients with CRP-H achieved shorter OS (8.6 vs 14.8 months; p=0.006), shorter PFS (3.3 vs 6.6 months; p=0.013), and lower ORR (24.7% vs 46.3%; p=0.015). After adjusting for relevant clinical variables, CRP-H was confirmed as an independent predictor of increased risk of death (HR 1.51, 95% CI: 1.09 to 2.11) and lower probability of achieving disease response (OR 0.34, 95% CI: 0.13 to 0.89). In cohort B, RNA-seq analysis demonstrated higher IL-6 expression on tumor cells of non-responders, along with a shorter PFS (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansAdenosineC-Reactive ProteinDrug Resistance, NeoplasmImmune Checkpoint InhibitorsInterleukin-6Tumor MicroenvironmentUp-RegulationReceptors, Immunologic

Stichwörter der Autor:innen

AdenosineImmune Checkpoint InhibitorsInflammationLung NeoplasmsTumor Microenvironment

Substanzen

AdenosineC-Reactive ProteinImmune Checkpoint InhibitorsInterleukin-6CRP protein, humanReceptors, ImmunologicIL6 protein, human

Autor:innen und Institutionen

  • Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA alessiocortellini@gmail.com abdulrafeh-naqash@ouhsc.edu.
  • Hematology / Oncology Division, East Carolina University, Greenville, South Carolina, USA.
  • Department of Internal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Brody School of Medicine, East Carolina University, Greenville, NC, USA.
  • Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK.
  • Oncology and Radiation Department, Oulu University Hospital, University of Oulu, MRC Oulu, Oulu, Finland.

ORCID-Profile: Sanna Iivanainen, David J Pinato, Alessio Cortellini

Förderung

  • Wellcome Trust
  • Wellcome Trust Strategic Fund
  • National Research Foundation of Korea
  • Lung Cancer Initiative
  • Coach Rock Foundation
  • Roger Williams Institute of Hepatology – Foundation for Liver Research
  • Associazione Italiana per la Ricerca sul Cancro
  • Samsung Research Funding & Incubation Center of Samsung Electronics

Zitieren

APA

Naqash, A. R., McCallen, J. D., Mi, E., Iivanainen, S., Marie, M. A., Gramenitskaya, D., Clark, J., Koivunen, J. P., Macherla, S., Jonnalagadda, S., Polsani, S., Jiwani, R. A., Hafiz, M., Muzaffar, M., Brunetti, L., Stroud, C. R. G., Walker, P. R., Wang, K., Chung, Y., …, & Cortellini, A. (2023). Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 11(10), e007310. https://doi.org/10.1136/jitc-2023-007310

Vancouver

Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, et al. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007310. doi:10.1136/jitc-2023-007310

BibTeX
@article{Naqash2023,
  author = {Naqash, Abdul Rafeh and McCallen, Justin D and Mi, Emma and Iivanainen, Sanna and Marie, Mona A and Gramenitskaya, Daria and Clark, James and Koivunen, Jussi Pekka and Macherla, Shravanti and Jonnalagadda, Sweta and Polsani, Shanker and Jiwani, Rahim Ali and Hafiz, Maida and Muzaffar, Mahvish and Brunetti, Leonardo and Stroud, Chipman R G and Walker, Paul R and Wang, Kun and Chung, Youngmin and Ruppin, Eytan and Lee, Se-Hoon and Yang, Li V and Pinato, David J and Lee, Joo Sang and Cortellini, Alessio},
  title = {Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {e007310},
  doi = {10.1136/jitc-2023-007310}
}
Kostenlos starten →